According to Eterna Therapeutics's latest financial reports and stock price the company's current Operating Margin is -6,475.42%. At the end of 2024 the company had an Operating Margin of -7,647.59%.
Year | Operating Margin | Change |
---|---|---|
2024 | -7,647.59% | -76% |
2023 | -31,869.12% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
![]() Baxter BAX | -5.98% | -99.91% | ๐บ๐ธ USA |
![]() Geron GERN | -226.73% | -96.50% | ๐บ๐ธ USA |
![]() Omeros Corporation OMER | -467.67% | -92.78% | ๐บ๐ธ USA |
![]() Sanofi SNY | 15.12% | -100.23% | ๐ซ๐ท France |
![]() Bio-Techne TECH | 16.02% | -100.25% | ๐บ๐ธ USA |
![]() Genetic Technologies GENE | -156.78% | -97.58% | ๐ฆ๐บ Australia |
![]() Teva Pharmaceutical Industries TEVA | -7.76% | -99.88% | ๐ฎ๐ฑ Israel |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.